Clinical Trial Update: SIGA-246 to Treat Smallpox [Phase 1]

View source ↗

Summary

Phase 1 trial of SIGA-246 for vaccinia infection has been withdrawn from further testing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaccinia Infection

Drugs mentioned

• SIGA-246

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Vaccinia | Phase 1 | Status: WITHDRAWN